Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
120 participants
INTERVENTIONAL
2015-05-01
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
However, evidence for a survival benefit of surgery for recurrent glioblastoma is scarce and relies entirely on retrospective analyses. While most retrospective analyses report an apparent survival benefit, an EORTC meta-analysis on second-line therapies found no survival difference in patients with or without surgery at recurrence. With regard to the risks and costs inherent to surgery for glioblastoma, a randomized controlled trial is required.
The purpose of the study is to compare the effect of craniotomy and tumor resection followed by adjuvant second-line therapy to no surgery followed by second-line therapy on overall survival, neurological status, and quality of life. Analysis of overall survival will be used to improve sample size estimation of a subsequent phase III trial for craniotomy and tumor resection of glioblastoma recurrence in cooperation with the EORTC.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
NCT06283927
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT02709226
Neoadjuvant Chemoradiation for Resectable Glioblastoma
NCT04209790
Trial of Preoperative Radiosurgery Versus Postoperative Stereotactic Radiotherapy for Resectable Brain Metastases
NCT05124236
Patient-derived Glioma Stem Cell Organoids
NCT04868396
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Glioblastoma is a malignant, locally invasive brain tumor whose prognosis remains grim despite various intense treatment modalities. In the past, radical surgery was met with skepticism due to the aggressive infiltrative character of the tumor. However, an increasing number of retrospective studies over the last decade suggest a survival benefit for surgery. A recent post-hoc analysis of a randomized controlled trial on the use of the surgical adjunct 5-ALA reported a prolonged overall survival from 11.9 to 16.7 months (evidence level 2a) after more extensive resection. Thus, maximal safe resection has become a mainstay of treatment for newly diagnosed glioblastoma, followed by adjuvant radio-chemotherapy.
Glioblastoma almost invariably recurs after a median of 6.9 months, leaving but few options for further treatment. Recurrence of glioblastoma after surgery and concomitant adjuvant therapy represents an additional therapeutic challenge and may be treated with second-line pharmacotherapy. In addition, a second surgery may also be considered in highly selected patients.
The rationale for surgery - maximum safe resection - is to prolong survival through reduction of tumor load, and, maybe due to an increased efficacy of adjuvant treatment. However, surgery carries risks of complications, that may result in a decreased functional and survival outcome. The crucial question therefore is whether, to what extent, and at what costs in terms of neurological risks a second resection prolongs survival.
Objective
The primary objective of this randomized trial is to compare survival outcome after surgery followed by adjuvant second-line therapy to no surgery followed by second-line therapy in recurrent glioblastoma. An auxiliary objective to primary objective is to compare the survival outcomes of operated patients to control in the subgroups stratified by extent of resection: incomplete resection (non-CRET) vs complete resection (CRET).
Secondary objectives are: assessment of recruitment for all screened patients, comparison of progression-free survival between treatment arms, evaluation of crossover and comparison of patient quality of life between treatment arms.
Safety objectives are: to assess neurological deficits, local infections and morbidity associated to surgery and hospital stay after surgery and during follow-up.
Methods
All patients (≥18 years) with a radiological suspicion of first recurrence of glioblastoma are screened for this trial. Patients eligible for study participation are informed on the treatment options for recurrent glioblastoma (surgery followed by adjuvant second-line therapy, second-line therapy, or palliative therapy alone) by the center investigators. Patients randomized to the control group will receive second-line therapy according to local guidelines. Patients randomized to the interventional group will receive a craniotomy and resection of the tumor followed by adjuvant second-line therapy. Outcome will be measured at 3 months intervals.
Recruitment rate and reason for non-inclusion will be monitored.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Second-line therapy alone
Second-line therapy alone
Second-line therapy alone
Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
Surgery followed by adjuvant second-line therapy
Surgery followed by adjuvant second-line therapy
Surgery followed by adjuvant second-line therapy
Surgery:
Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.
Adjuvant second-line therapy:
Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Surgery followed by adjuvant second-line therapy
Surgery:
Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.
Adjuvant second-line therapy:
Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol.
Second-line therapy alone
Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥18 years of age
* Prior resection of glioblastoma confirmed by histology
* Glioblastoma pretreated with standard radiotherapy without or with temozolomide
* First progression according to RANO criteria
* First progression not within 3 months after completion of radiation therapy
* Complete removal of contrast-enhancing lesion considered feasible without significant risk of permanent speech or motor function according to MRI as confirmed by study eligibility committee after screening and prior to recruitment
* No encroachment of the M1 or A1 segments of the medial and anterior cerebral artery on MRI
* No contrast enhancement in presumed speech and primary motor areas on MRI
* No midline shift on MRI
* No contrast enhancing ventricular spread, multifocal recurrence, meningeosis carcinomatosa or infiltration of the contra-lateral hemisphere on MRI
* No contra-indication for surgery
* Good functional status (KPS ≥ 70)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
Insel Gruppe AG, University Hospital Bern
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philippe Schucht, Prof. Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Dep. of Neurosurgery, Inselspital Bern
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Universitätsklinikum Innsbruck
Innsbruck, , Austria
Johannes Kepler University Linz University, Clinic for Neurosurgery
Linz, , Austria
Medical University of Vienna, Department of Neurosurgery
Vienna, , Austria
Centre Hospitalier Universitaire Dijon Bourgogne, Department of Neurosurgery
Dijon, , France
Hospices Civils de Lyon - CHU de Lyon, Department of Neuro-Oncology
Lyon, , France
Assistance Publique - Hôpitaux de Marseille, Department of Neuro-Oncology
Marseille, , France
Centre Hospitalier Universitaire de Nice, Department of Neurosurgery
Nice, , France
Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Neurosurgery
Paris, , France
Centre Hospitalier Universitaire de Saint-Étienne, Department of Neurosurgery
Saint-Etienne, , France
Institut de Cancérologie Strasbourg Europe (ICANS), Department of Oncology
Strasbourg, , France
Centre Hospitalier Régional et Universitaire de Tours (CHRU Tours), Department of Neurosurgery
Tours, , France
Helios Klinikum Erfurt
Erfurt, , Germany
Universitätsklinikum Münster
Münster, , Germany
Department of Neurosurgery, Hospital of Larissa & General Hospital of Larissa
Larissa, , Greece
Department of Neurosurgery, Amsterdam University Medical Center
Amsterdam, , Netherlands
Department of Neurosurgery, Radboud University Medical Center, Nijmegen
Nijmegen, , Netherlands
Department of Neurosurgery, Haaglanden Medical Center, The Hague
The Hague, , Netherlands
Department of Neurosurgery, Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria
Lisbon, , Portugal
Department of Neurosurgery, L'Hospitalet de Llobregat, Barcelona
Barcelona, , Spain
University of Gothenburg, Department of Clinical Neuroscience
Gothenburg, , Sweden
University Hospital of Umeå, Department of Diagnostics and Intervention
Umeå, , Sweden
Universitätsspital Basel
Basel, , Switzerland
Dep. of Neurosurgery, Bern University Hospital
Bern, , Switzerland
Dep. of Neurosurgery, Centre hospitalier universitaire vaudois
Lausanne, , Switzerland
Ospedale Regionale di Lugano
Lugano, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Alexandre Rainha Campos, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
368/14
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.